Delcath Systems Inc. (NASDAQ: DCTH)
$7.96
-0.0050 ( -0.06% ) 156.4K
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Market Data
Open
$7.96
Previous close
$7.96
Volume
156.4K
Market cap
$221.45M
Day range
$7.92 - $8.06
52 week range
$2.25 - $9.18
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4/a | Other | 1 | May 16, 2024 |
4 | Insider transactions | 1 | May 16, 2024 |
4 | Insider transactions | 1 | May 16, 2024 |
4/a | Other | 1 | May 16, 2024 |
4/a | Other | 1 | May 16, 2024 |
8-k | 8K-related | 14 | May 14, 2024 |
10-q | Quarterly Reports | 91 | May 14, 2024 |
8-k | 8K-related | 13 | Apr 26, 2024 |
ars | Annual reports | 1 | Apr 12, 2024 |
def | Proxies and info statements | 22 | Apr 12, 2024 |